NCT00228020View on ClinicalTrials.gov

Study of Safety and Efficacy of a Basiliximab, Mycophenolate Mofetil, Cyclosporine Microemulsion and Prednisone Combination Treatment Regimen in Pediatric Renal Allograft Recipients

PHASE3CompletedINTERVENTIONAL
Enrollment

212

Participants

Timeline

Start Date

May 31, 2001

Primary Completion Date

January 31, 2006

Conditions
Pediatric Kidney Transplantation
Interventions
DRUG

basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent)

DRUG

MMF, cyclosporine, steroids

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00228020 - Study of Safety and Efficacy of a Basiliximab, Mycophenolate Mofetil, Cyclosporine Microemulsion and Prednisone Combination Treatment Regimen in Pediatric Renal Allograft Recipients | Biotech Hunter | Biotech Hunter